Tempus AI (TEM) closed at $63.62 on November 18, 2026, then traded at $65.74 in the latest futures snapshot, while the company’s third-quarter 2026 revenue of $411.5 million helped support a fresh ...
Tempus AI reported third-quarter 2026 revenue of $411.5 million on November 2, 2026, with management highlighting 32% unit growth in oncology and 33% revenue growth in Data & Applications. That matters because it shows the business is still scaling through its core precision-medicine and data platforms, which is exactly what analysts are leaning on in their target updates. Needham raised its price target to $89 from $75 and kept a Buy rating, citing the quarter’s revenue and adjusted EBITDA beat, while Reuters-quoted commentary via Investing.com pointed to more than $550 million of bookings year-to-date, including strategic wins and extensions from Merck and Bristol Myers Squibb.
Yahoo Finance shows TEM at $63.62 at the close on November 18, with a $63.86 after-hours print, and lists an average analyst target of $89.56 versus a high of $120. StockAnalysis also shows 20 analysts with a consensus Buy rating and the same $89.56 average target. That puts the stock in a clear tug-of-war: operating progress and analyst support on one side, versus a price that has not yet reclaimed the trend structure on the other.
TEM’s latest price action is trying to stabilize, but the technical backdrop is not clean. 34. That is a short-term distribution setup, not a confirmed trend reversal.
Source link







